Soligenix

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1987-01-01

Employees: 15

Market Cap: $8.8M

Website: http://www.soligenix.com

Introduction: Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing to...

Clinical Trials

Confirmatory Study of Topical HyBryte™ Vs. Placebo for the Treatment of CTCL

Phase 3

Recruiting

Conditions: Mycosis Fungoides
Cutaneous T Cell Lymphoma
CTCL/ Mycosis Fungoides
CTCL

Interventions: Drug: Placebo
Drug: Hypericin

First Posted Date: 2024-06-24

Last Posted Date: 2024-12-20

Lead Sponsor: Soligenix

Target Recruit Count: 80

Registration Number: NCT06470451

Locations: 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸
Therapeutics Clinical Research, San Diego, California, United States

and more 9 locations

Dusquetide for the Treatment of Behcet's Disease

Phase 2

Recruiting

Conditions: Behçet Disease

Interventions: Drug: Dusquetide

First Posted Date: 2024-04-26

Last Posted Date: 2024-12-06

Lead Sponsor: Soligenix

Target Recruit Count: 25

Registration Number: NCT06386744

Locations: 🇹🇷
Istanbul University - Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, Turkey

HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL

Phase 2

Completed

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Interventions: Drug: Mechlorethamine Topical Gel
Drug: Hypericin

First Posted Date: 2023-11-28

Last Posted Date: 2024-07-03

Lead Sponsor: Soligenix

Target Recruit Count: 10

Registration Number: NCT06149247

Locations: 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States

Topical SGX302 for Mild-to-Moderate Psoriasis

Phase 2

Recruiting

Conditions: Plaque Psoriasis
Psoriasis
Psoriasis Vulgaris

Interventions: Drug: Hypericin
Drug: Placebo

First Posted Date: 2022-07-01

Last Posted Date: 2024-11-27

Lead Sponsor: Soligenix

Target Recruit Count: 47

Registration Number: NCT05442190

Locations: 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States

PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

Phase 2

Completed

Conditions: Cutaneous T-Cell Lymphoma/Mycosis Fungoides

Interventions: Drug: Hypericin

First Posted Date: 2022-05-19

Last Posted Date: 2023-06-07

Lead Sponsor: Soligenix

Target Recruit Count: 9

Registration Number: NCT05380635

Locations: 🇺🇸
Rochester Skin Lymphoma Medical Group, Fairport, New York, United States

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

Phase 3

Completed

Conditions: Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
Oral Mucositis

Interventions: Drug: SGX942
Drug: Placebo

First Posted Date: 2017-08-02

Last Posted Date: 2022-11-08

Lead Sponsor: Soligenix

Target Recruit Count: 266

Registration Number: NCT03237325

Locations: 🇫🇷
CROM-Osny, Osny, France
🇺🇸
Hackensack Meridian Health, Neptune, New Jersey, United States
🇫🇷
Clinique Victor Hugo, Le Mans, France

and more 50 locations

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Phase 3

Completed

Conditions: Cutaneous T-Cell Lymphoma

Interventions: Drug: SGX301 (synthetic hypericin)
Drug: Placebo

First Posted Date: 2015-05-19

Last Posted Date: 2022-04-15

Lead Sponsor: Soligenix

Target Recruit Count: 169

Registration Number: NCT02448381

Locations: 🇺🇸
Therapeutics Clinical Research, San Diego, California, United States
🇺🇸
Olympian Clinical Research, Clearwater, Florida, United States
🇺🇸
Leon Medical Research, Miami, Florida, United States

and more 30 locations

A Dose Escalating Study of SGX942 for Oral Mucositis in Patients With Head and Neck Cancer

Phase 2

Completed

Conditions: Oral Mucositis

Interventions: Drug: Placebo
Drug: SGX942

First Posted Date: 2013-12-17

Last Posted Date: 2017-08-28

Lead Sponsor: Soligenix

Target Recruit Count: 111

Registration Number: NCT02013050

Locations: 🇺🇸
Markey Cancer Center-University of Kentucky, Lexington, Kentucky, United States

Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)

Phase 2

Terminated

Conditions: Chronic Gastrointestinal Graft vs Host Disease

Interventions: Drug: orBec
Drug: Placebo

First Posted Date: 2013-08-20

Last Posted Date: 2018-11-01

Lead Sponsor: Soligenix

Target Recruit Count: 2

Registration Number: NCT01925950

Locations: 🇺🇸
John Theurer Cancer Center, Hackensack, New Jersey, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

A Dose Ranging Study of Delayed Release Beclomethasone for Prevention of Acute Enteritis in Patients With Rectal Cancer

Phase 1

Completed

Conditions: Enteritis

Interventions: Drug: SGX201 (delayed release beclomethasone 17,21-dipropionate)

First Posted Date: 2010-02-23

Last Posted Date: 2012-12-17

Lead Sponsor: Soligenix

Target Recruit Count: 16

Registration Number: NCT01073384

Locations: 🇺🇸
Boston University, Boston, Massachusetts, United States
🇺🇸
Northwestern University Medical Center, Chicago, Illinois, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy